Abstract
Type 2 diabetes, cardiovascular disease (CVD) and the cardiovascular effect of antidiabetic drugs are important issues in the order of the day. In fact, type 2 diabetes is a disease in increasing prevalence, essentially due to unhealthy lifestyle habits. Type 2 diabetes, in association with obesity and other cardiovascular risk factors, results in the best scenario for the development of CVD, the leading cause of morbidity and mortality in patients with type 2 diabetes. Thus, diabetes treatment is an individualized and complex challenge in which targeting cardiovascular risk factors is an important decision factor. Given the cardiovascular adverse events associated to rosiglitazone, both Food and Drug Administration and the European Medicines Agency currently require the demonstration of cardiovascular safety of new antidiabetic drugs. For so, clinical trials to guarantee this cardiovascular safety are now obligatory. This review aims to summarize the available evidence on the cardiovascular effects and safety of the major drugs used in diabetes treatment, and also to give an overview of upcoming and ongoing clinical trials in this field. Our believe is that this document will be extremely helpful for all the medical doctors who take care of diabetic patients, namely primary care physicians, internal medicine doctors, diabetologists, endocrinologists and less well experienced personnel such as young doctors in training.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
